Holmberg et al., 1981 - Google Patents

Factor VIII: C and VIII: CAg response in patients with haemophilia A and von Willebrand's disease after administration of different factor VIII concentrates or plasma

Holmberg et al., 1981

Document ID
8778543943142647213
Author
Holmberg L
Borge L
Nilsson I
Publication year
Publication venue
British Journal of Haematology

External Links

Snippet

Factor VIII procoagulant activity (VIII: C) and factor VIII procoagulant antigen (VIII: CAg) were studied in seven patients with haemophilia A after administration of three different factor VIII concentrates or plasma. The in vivo recovery of VIII: CAg was less than that of VIII: C and the …
Continue reading at onlinelibrary.wiley.com (other versions)

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/75—Fibrinogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/827—Proteins from mammals or birds
    • Y10S530/829—Blood

Similar Documents

Publication Publication Date Title
Brinkhous et al. Purified human factor VIII procoagulant protein: comparative hemostatic response after infusions into hemophilic and von Willebrand disease dogs.
Gralnick et al. Studies of the human factor VIII/von Willebrand factor protein. III. Qualitative defects in von Willebrand's disease.
Tuddenham et al. Response to infusions of polyelectrolyte fractionated human factor VIII concentrate in human haemophilia A and von Willebrand's disease
Sixma et al. Adhesion of platelets to human artery subendothelium: effect of factor VIII-von Willebrand factor of various multimeric composition
Berntorp et al. Use of a high-purity factor VIII concentrate (Hemate P) in von Willebrand’s disease
Sultan et al. Electrophoretic heterogeneity of normal factor VIII/von Willebrand protein, and abnormal electrophoretic mobility in patients with von Willebrand's disease
FI103510B (en) Method for isolating factor VIII
Berntorp et al. Biochemical and in vivo properties of commercial virus‐inactivated factor VIII concentrates
CA2213721C (en) Method for stabilizing platelets
Menache et al. Pharmacokinetics of von Willebrand factor and factor VIIIC in patients with severe von Willebrand disease (type 3 VWD): estimation of the rate of factor VIIIC synthesis
Nilsson IN MEMORY OF ERIK JORPES: von Willebrand's Disease from 1926–1983
Nilsson et al. Characteristics of the factor VIII protein and Factor XIII in various factor VIII concentrates
Nilsson et al. Factor VIII concentrate prepared from DDAVP stimulated blood donor plasma
Holmberg et al. Factor VIII: C and VIII: CAg response in patients with haemophilia A and von Willebrand's disease after administration of different factor VIII concentrates or plasma
Sakariassen et al. Association between bleeding time and platelet adherence to artery subendothelium
Schneider‐Trip et al. Studies on the mechanism of ristocetin‐induced platelet aggregation: binding of factor VIII to platelets
Mazurier et al. In vitro and in vivo characterization of a high‐purity, solvent/detergent‐treated factor VIII concentrate: evidence for its therapeutic efficacy in von Willebrand's disease
Cumming et al. Clinical and laboratory evaluation of National Health Service factor VIII concentrate (8Y) for the treatment of von Willebrand's disease
Fricke et al. Characterization of von Willebrand factor in factor VIII concentrates
Zucker et al. The in vitro association of antihemophilic factor and von Willebrand factor
Uchiba et al. Effect of human urinary thrombomodulin on endotoxin‐induced intravascular coagulation and pulmonary vascular injury in rats
Smiley et al. Studies on the prolonged bleeding time in von Willebrand's disease
Åberg et al. Effect of dextran 70 on factor VIII and platelet function in von Willebrand's disease
Lewis et al. Chemical, clinical and immunological studies on the products of human plasma fractionation: XXXII. The coagulation defect in hemophilia. An in vitro and in vivo comparison of normal and hemophilic whole blood, plasma and derived plasma protein fractions
Lopez‐Fernandez et al. Assessment of multimeric structure and ristocetin‐induced binding to platelets of von Willebrand factor present in cryoprecipitate and different factor VIII concentrates